Preservative-free influenza vaccine

Immunology Letters

Volumn 71, Issue 2, 2000, Pages 91-96

  Banzhoff, Angelika ^a   Schwenke, Carsten ^a   Febbraro, Salvatore ^b  

^a Chiron Behring GmbH & Co   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Influenza virus; Preservative; Seroconversion; Thimerosal; Vaccine

Indexed keywords

INFLUENZA VACCINE; PRESERVATIVE; THIOMERSAL;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHARYNGITIS; PRESERVATION; PRIORITY JOURNAL; RHINITIS; SEROCONVERSION; VACCINE PRODUCTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; DRUG TOLERANCE; ERYTHEMA; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; MIDDLE AGED; PAIN; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; SAFETY; THIMEROSAL; VACCINES, INACTIVATED;

EID: 0034141976     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(99)00171-6     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. Prevention and control of influenza: Recommendations of the advisory committee on immunization practices (ACIP), MMWR Morb. Mortal. Weekly Rep. 45 (RR-5) (1996) 3.
2. La Montagne J.R., Noble G.R., Quinnan G.V. et al. Rev. Infect. Dis. 5:1983;723-736.
3. Oxford J.S., Schild G.C., Potter C.W., Jennings R.J. Hygiene. 82:1979;51-61.
4. Dorrell L., Hassan I., Marshall S., Chakraverty P., Ong E. Int. J. STD AIDS. 8:1997;776-779.
5. McElhaney J.E., Beattie B.L., Devine R., Grynoch R., Toth E.L., Bleackly R.C. J. Am. Geriatr. Soc. 38:1990;652-658.
6. Gross P.A., Hermogenes A.W., Sacls H.S., Lau J., Levandowski R.A. Ann. Intern. Med. 123:1995;518-527.
7. Carrat F., Valleron A.J. J. Epidemiol. Commun. Health. 49:1995;419-425.
8. Heller L., Bottiger M. Symposium Series on Immunobiological Standards. 20:1973;258-264 Karger, Basel.
9. Wesselius-de Casparis A., Hogerzeil H.H.W., van Beek A. Symposium Series on Immunobiological Standards. 20:1973;264-274 Karger, Basel.
10. Wilde J.A., McMillan J.A., Serwint J., Butta J., O'Riordan M.A., Steinhoff M.C. J. Am. Med. Assoc. 281:1999;908-913.
11. Summary of product characteristics. Begrivac® 98/99. Chiron Behring GmbH & Co, Marburg, Germany.
12. Grandjean P., Budtz-Jorgensen E., White R.F., Jorgensen P.J., Weihe P., Debes F., Keiding N. Am. J. Epidemiol. 150:1999;301-305.
13. Centers for Disease Control and Prevention, MMWR Morb. Mortal Weekly Rep. 46 (RR-9) (1997) 1-25.
14. Aberer W. Contact Dermatitis. 24:1991;6-10.
15. Kirkland L.R. South Med. J. 83:1990;497-499.
16. Coombs R.R.A., Gell P.G.H. Gell P.G.H., Coombs R.R.A., Lachmann P.J. Clinical Aspects of Immunology. 1975;761-781 Blackwell, Oxford.
17. Note for Guidance on Harmonization of Requirements for Influenza Vaccines: CPMP/BWP/214/96.
18. Nichol K.L., Margolis K.L., Lind A. et al. Arch. Intern. Med. 156:1996;1546-1550.
19. Barry D.W., Mayner R.E., Staton E. et al. Am. J. Epidemiol. 104:1976;34-46.
20. Barry D.W., Mayner R.E., Hochstein H.D. et al. Am. J. Epidemiol. 104:1976;47-59.
21. Osawa J., Kitamura K., Ikezawa Z., Nakajima H. Contact Dermatitis. 24:1991;178-182.
22. McKenna K.E. Contact Dermatitis. 40:1999;158-159.
23. Patrizi A., Rizzoli L., Vincenzi C., Trevisi P., Tosti A. Contact Dermatitis. 40:1999;94-97.
24. Schafer T., Enders F., Przybilla B. Contact Dermatitis. 32:1995;114-116.
25. Thimerosal in vaccines: A joint statement of the American academy of pediatrics and the public health service, MMWR Morb. Mortal Weekly Rep. 48 (1999) 563-565.